Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
65.17B
Market cap65.17B
Price-Earnings ratio
15.29
Price-Earnings ratio15.29
Dividend yield
0.57%
Dividend yield0.57%
Average volume
1.30M
Average volume1.30M
High today
$635.00
High today$635.00
Low today
$620.35
Low today$620.35
Open price
$631.48
Open price$631.48
Volume
1.19M
Volume1.19M
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

With a market cap of 65.17B, Regeneron(REGN) trades at $621.52. The stock has a price-to-earnings ratio of 15.29 and currently yields dividends of 57.0%.

As of 2026-05-28, Regeneron(REGN) stock has fluctuated between $620.35 and $635.00. The current price stands at $621.52, placing the stock +0.2% above today's low and -2.1% off the high.

Regeneron(REGN) shares are trading with a volume of 1.19M, against a daily average of 1.3M.

In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.

In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.

REGN News

MarketWatch 23h
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

...

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Investor's Business Daily 1d
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Technology Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results Licensing Apogee Therapeutics (APGE) reported mixed results for its experimental eczema tr...

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results
Simply Wall St 3d
A Look At Regeneron Pharmaceuticals Valuation After Recent Trial Wins And New Research Partnership

Regeneron Pharmaceuticals (REGN) is back in focus after three pipeline updates in quick succession, including early Lynozyfic data in systemic AL amyloidosis, a...

A Look At Regeneron Pharmaceuticals Valuation After Recent Trial Wins And New Research Partnership

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
25.8%
Sell
0%

More REGN News

Simply Wall St 4d
Why Regeneron Is Down 8.5% After Melanoma Trial Miss and New Legal Scrutiny - And What's Next

Earlier in May 2026, Regeneron Pharmaceuticals reported that its Phase 3 trial of fianlimab plus cemiplimab in first-line metastatic melanoma did not reach stat...

Why Regeneron Is Down 8.5% After Melanoma Trial Miss and New Legal Scrutiny - And What's Next
TipRanks 5d
Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

Analysts are intrested in these 5 stocks: ( (REGN) ), ( (CRCL) ), ( (BURL) ), ( (ROST) ) and ( (PBA) ). Here is a breakdown of their recent ratings and the rati...

Simply Wall St 6d
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive Phase 1/2 data for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, with all patients achieving...

Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus
TipRanks 6d
Regeneron’s ROXI-PALISADE Trial Targets Safer Clot Prevention in Peripheral Artery Disease

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intel...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.